Celcuity (NASDAQ:CELC) Releases Earnings Results, Beats Estimates By $0.02 EPS

Celcuity (NASDAQ:CELC) issued its earnings results on Thursday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Fidelity Earnings reports.

NASDAQ CELC traded up $0.26 during trading hours on Friday, hitting $14.30. The company had a trading volume of 4,400 shares, compared to its average volume of 7,599. The company has a debt-to-equity ratio of 0.01, a quick ratio of 25.26 and a current ratio of 25.25. The business has a 50 day moving average of $16.28 and a 200-day moving average of $19.76. Celcuity has a 1-year low of $13.49 and a 1-year high of $29.96. The company has a market cap of $157.07 million, a PE ratio of -19.32 and a beta of 0.65.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Celcuity from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Friday, October 11th. ValuEngine upgraded shares of Celcuity from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.

About Celcuity

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Recommended Story: What are the benefits of buying treasury bonds?

Earnings History for Celcuity (NASDAQ:CELC)

Leave a Reply

Your email address will not be published. Required fields are marked *

*